Form 8-K - Current report:
SEC Accession No. 0001829126-25-008237
Filing Date
2025-10-20
Accepted
2025-10-20 08:47:58
Documents
14
Period of Report
2025-10-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K novabay_8k.htm   iXBRL 8-K 85940
2 EXHIBIT 3.1 novabay_ex3-1.htm EX-3.1 9411
3 EXHIBIT 4.1 novabay_ex4-1.htm EX-4.1 112811
  Complete submission text file 0001829126-25-008237.txt   410809

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nby-20251016.xsd EX-101.SCH 2984
5 XBRL LABEL FILE nby-20251016_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE nby-20251016_pre.xml EX-101.PRE 22339
16 EXTRACTED XBRL INSTANCE DOCUMENT novabay_8k_htm.xml XML 3810
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Filer) CIK: 0001389545 (see all company filings)

EIN.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33678 | Film No.: 251402409
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)